United States

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

11:29am EDT
Change (% chg)

0.25kr (+4.67%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Active Biotech AB says no dividend would be paid
Friday, 27 May 2016 02:33am EDT 

Active Biotech Ab : Annual general meeting of active biotech ab . In accordance with board of directors' proposal, it was resolved that no dividend would be paid .Board members and managing director were discharged from liability with respect to their management of company for 2015.  Full Article

Active Biotech plans to develop tasquinimod for treatment of multiple myeloma
Wednesday, 23 Mar 2016 03:40am EDT 

Active Biotech AB:Plans to develop tasquinimod for the treatment of multiple myeloma.Says patent application for the treatment of multiple myeloma with the company's compound tasquinimod will be public within short.Says with this application, treatment of multiple myeloma with tasquinimod is potentially protected until 2035.Preclinical program was performed and very good results were achieved in models for multiple myeloma.Says will actively seek a collaboration partner for the development of tasquinimod within this indication.During 2016 orphan drug status applications for tasquinimod treatment of multiple myeloma are planned to be submitted to authorities in the EU and USA.Multiple myeloma is an incurable form of blood cancer where the plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed.Says total market for multiple myeloma drugs amounted to 7.8 billion usd in 2013 (globaldata 2015).  Full Article

Active Biotech says stops higher doses MS trials of Laquinimod
Monday, 4 Jan 2016 09:01am EST 

Active Biotech AB:Says Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials.Says ‍occurrence of cardiovascular events, none of which was fatal, in eight patients​.Says ‍both trials, concerto and arpeggio, are continuing lower-dose arms (0.6mg daily), and participants in trials will be provided with an update to confirm re-consent for participation​.  Full Article

BRIEF-Active Biotech Q2 operating loss 23.1 mln SEK

* Active biotech ab q2 sales 5.1 million sek Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)